The Centers for Medicare and Medicaid Services has asked the public whether Medicare should develop and pay for intensive lifestyle interventions aimed at Alzheimer's disease and related dementias. The question appears as a request for information inside the calendar year 2027 Physician Fee Schedule proposed rule (file code CMS-1848-P), which CMS issued on 14 July 2026 and which was published in the Federal Register on 16 July 2026 at 91 FR 43842. The rule's table of contents lists the section as "Request for Information on Intensive Lifestyle Interventions To Slow Progression of Alzheimer's Disease". The 60 day comment period closes on 14 September 2026, and comments are taken through regulations.gov under docket CMS-2026-2377-0002.

A request for information is not a proposal. CMS is not proposing a benefit, a code, a payment rate or an eligibility rule for such programmes in this document; it is collecting material that could inform a future rule. The dementia question sits alongside other requests for information in the same rule, including one on redesigning primary care payment, one on community based palliative care, one on the Current Procedural Terminology coding system, and one on duplicate laboratory and imaging testing. Nothing in the docket obliges the agency to act, and any coverage decision would have to come through separate rulemaking.

The evidence CMS is inviting comment on is real but limited. The largest recent test is U.S. POINTER, a single blind, multicentre randomised clinical trial that enrolled 2,111 adults aged 60 to 79 at five American sites between May 2019 and March 2023, with final follow up on 14 May 2025. Published in JAMA on 26 August 2025, it compared a structured multidomain programme (exercise, the MIND diet, cognitive training, social engagement and cardiometabolic monitoring, with frequent team meetings) against a self guided version of the same advice. Both groups improved on the global cognitive composite; the structured group improved faster by 0.029 standard deviations per year (95 per cent confidence interval 0.008 to 0.050, P =.008). Mean age was 68.2 years, 68.9 per cent of participants were female, and 89 per cent completed the year two assessment.

The smaller body of work in people who already have symptoms is smaller still. A phase 2 randomised controlled trial led by Dean Ornish and colleagues, published in Alzheimer's Research and Therapy on 7 June 2024, enrolled 51 participants with mild cognitive impairment or early dementia due to Alzheimer's disease and ran for 20 weeks against usual care, with 40 week follow up reported subsequently after the control group crossed over. Fifty one people is a small trial by any standard, and its authors describe it as such. Whether a programme of that intensity can be delivered at Medicare scale, by whom, for how long and at what cost, is precisely what the agency has asked the public to tell it.